Insider Selling: Kenneth Dipietro Unloads 1,290 Shares of Biogen Idec Stock (BIIB)
Biogen Idec (NASDAQ:BIIB) EVP Kenneth Dipietro sold 1,290 shares of the stock on the open market in a transaction dated Thursday, February 13th. The stock was sold at an average price of $316.81, for a total transaction of $408,684.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on BIIB shares. Analysts at TheStreet reiterated a “buy” rating on shares of Biogen Idec in a research note on Friday, February 7th. Separately, analysts at Zacks upgraded shares of Biogen Idec from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 4th. They now have a $375.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of Biogen Idec from $310.00 to $360.00 in a research note on Thursday, January 30th. They now have a “buy” rating on the stock. Nine research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. Biogen Idec currently has an average rating of “Buy” and an average target price of $301.00.
Shares of Biogen Idec (NASDAQ:BIIB) traded down 0.10% during mid-day trading on Friday, hitting $328.29. 1,056,135 shares of the company’s stock traded hands. Biogen Idec has a 52-week low of $160.42 and a 52-week high of $331.74. The stock’s 50-day moving average is $300.3 and its 200-day moving average is $257.5. The company has a market cap of $77.605 billion and a P/E ratio of 42.08.
Biogen Idec (NASDAQ:BIIB) last released its earnings data on Wednesday, January 29th. The company reported $2.34 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.27 by $0.07. The company had revenue of $2.00 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the prior year, the company posted $1.40 earnings per share. The company’s quarterly revenue was up 38.6% on a year-over-year basis. Analysts expect that Biogen Idec will post $11.33 EPS for the current fiscal year.
Biogen Idec Inc (NASDAQ:BIIB) is a global biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.